← All trials
NCT04197934
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 20, 2019
- Primary completion
- Dec 20, 2022
- Completion date
- Dec 20, 2022
- First posted
- —
- Last posted
- —
- Enrollment
- 72
- Arms / groups
- 4 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Mayo ClinicLead sponsor
- National Cancer Institute (NCI)Collaborator
- Mayo ClinicOverall official - principal investigator
- Food and Drug AdministrationCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.